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Only chiral liquid chromatography and high-performance 
thin-layer chromatographic methods have been developed 
for determination of Escitalopram Oxalate individually.[3,4]
Moreover, the literature survey revealed that, no method has 
been reported for estimation of Escitalopram Oxalate in 
dosage forms by spectrophotometric method individually 
so far; hence an attempt has been made to develop a simple, 
accurate, and economic analytical method. The papers 
describe zero order spectrophotometric method for the 
estimation of Escitalopram Oxalate in tablet, using 80% 
(v/v) aqueous methanol as solvent.
MATERIALS AND METHODS
Materials
Instrument
A UV-VIS Spectrophotometer, model Shimadzu 1601 
INTRODUCTION
Escitalopram  Oxalate,  chemically,  S(+)-1-(3-
dimethylaminopropyl)-1-(4-fluorophenyl)-1, 
3-dihydroisobenzofuran-5-carbonitrile hydrogen oxalate, 
is the pure S-enantiomer (single enantiomer) racemic 
bicyclic phthalane derivative of citalopram used as an 
antidepressant. The molecular weight of Escitalopram 
Oxalate is 414.43. Escitalopram Oxalate is white crystalline 
powder having melting point 146-1490C. It is Soluble in 
alcohol, sparingly soluble in water and slightly soluble in 
acetone. The antidepressant and antiobsessive-compulsive 
actions of escitalopram are presumed to be linked to 
its inhibition of CNS neuronal uptake of serotonin. 
Escitalopram blocks the reuptake of serotonin at the 
serotonin reuptake pump of the neuronal membrane, 
enhancing the actions of serotonin on 5HT1A auto 
receptors.[1,2] Escitalopram oxalate is not official in any 
pharmacopoeia; hence no official method is available for 
estimation of Escitalopram oxalate in tablet formulation. 
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was employed with spectral bandwidth of 1.8 nm and a 
wavelength accuracy of ±0.5 nm with a pair of matched 
quartz cells of 10mm optical path length. Digital weighing 
balance model HR 200 (Afcoset) and ultra sonic bath, SW 
45 (Toshcon/ Tosniwal) was also used.
Escitalopram oxalate was obtained as a gift sample from 
DD Pharmaceuticals. Sitapura, Jaipur (Raj.). Methanol was 
procured AR grade, (Merck) and Distilled water (In house 
production) was used for preparing solutions. 80% v/v 
methanol in water was selected as a reference solvent. All 
other reagents and chemicals were of analytical reagent 
grade. 
Methods
Selection and optimization of  solvent system
10 mg Escitalopram Oxalate was dissolved in solvent 
system of different ratio of methanol and water (2:8, 
6:4 and 8:2) and final volume was adjusted to 100 ml 
and allowed to stand for 4-5 hours. Each sample was 
visually examined and scanned under double beam UV-
visible spectrophotometer. The solvent system having 
methanol and water (8:2) was selected because drug gave 
optimum absorbance value with better stability and a clear 
transparent solution was obtained in this solvent system.
Preparation of  standard solution
Standard stock solution containing Escitalopram Oxalate 
was prepared by dissolving 10 mg of Escitalopram 
Oxalate in 100 ml of reference solvent to obtain stock 
solution containing 100 µg/ml of drug. Standard stock 
solution was diluted with reference solvent in a series to 
obtain working standard solutions in concentration range 
of 2-20 µg/ml. Solutions were scanned in the UV range   
[Figure 1] and calibration curve was plotted between 
absorbance and concentrations. 
Preparation of  sample solution:
Ten tablets each of label claimed 20 mg of Escitalopram 
Oxalate (Brand I) and label claimed 10 mg of Escitalopram 
Oxalate (Brand II) were triturated into fine powder. Tablet 
powder equivalent to 20 mg (Brand I) and 10 mg (Brand 
II) of Escitalopram Oxalate was transferred to 100 ml 
volumetric flask separately and dissolved in reference 
solvent by sonicating for 20 min. The final volume was 
adjusted up to the mark with reference solvent to give 
stock solution of 200 µg/ml (Brand I) and 100 µg/ml 
(Brand II). These solutions were filtered through whatmann 
filter paper and further diluted suitably to obtain six 
replicates of 20 µg/ml solutions (Brand I) and 10 µg/ml 
solutions (Brand II). These solutions were analyzed using 
spectrophotometer. 
VALIDATION OF PROPOSED METHOD[5-8]
Specificity
For specificity study, any possible bias was determined by 
comparison of result of assay value obtained in presence 
of excipients to assay value without excipients mixture. 
Assay bias was evaluated by calculating the percentage 
interference. 
Linearity study
Linearity of the method was investigated by diluting the 
stock solutions to give a concentration range of 2-20µg/
ml. The calibration curve was constructed at optimum 
experimental conditions by plotting absorbance against 
concentration. 
REPEATABILITY
Repeatability is performed by intra and inter - day precision. 
Intra-day precision was determined by analyzing the three 
different concentrations of drug for three times in the same 
day. Inter-day precision was determined by analyzing the 
three different concentrations of the drug for three days 
in a week.
RECOVERY STUDY
To study validity and reproducibility of proposed method, 
recovery studies were carried out by adding known 
amount of drug to preanalysed sample at three different 
levels (80%, 100% and 120%) and the percentage mean 
recoveries of Escitalopram Oxalate in Brand I and Brand 
II were calculated. 
Figure 1: Overlain spectra of 2, 4, 6, 8, 10, 12, 14, 16, and 18 µg/ml of 
Standard Escitalopram Oxalate Solutions in 80%v/v aqueous methanolSharma, et al. J Young Pharm. 2010;2(4): 420-423
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Limits of Detection (LOD) and Limit of Quantification 
(LOQ)
The LOD and LOQ were separately determined based on 
the standard calibration curve. To estimate the LOD and 
LOQ, diluent was scanned under UV region six times and 
the signal-to-noise ratio (S/N) was determined. LOD and 
LOQ were regarded as the amounts for which S/N was 
3:1 and 10:1, respectively.
RESULTS AND DISCUSSION
The zero order spectra of Escitalopram Oxalate were 
recorded between 200 and 400 nm and the maximum 
wavelength of Escitalopram Oxalate in 80%v/v aqueous 
methanol was found to be 238 nm. A clear transparent 
solution and stable spectra of Escitalopram Oxalate 
was obtained in methanol: water (8:2) for more than 
240 minutes showing stability of Escitalopram Oxalate 
in this solvent system. Escitalopram Oxalate follows 
linearity in the concentration range of 2-20 µg/ml with 
the regression equation y=0.0488x-0.0006, where y is 
amplitude of the peak at 238 nm of zero order spectra 
and x is the concentration of the sample in µg/ml. High 
value of correlation coefficient (0.9999) indicates good 
linearity and adherence of method to Beer’s law within the 
concentration range tested by this method [Table 1]. The 
molar absorptivity of Escitalopram Oxalate was found 
20.222x103 Lit/mole/cm. All parameters of the proposed 
method were validated as per the ICH guidelines. Average 
interference and relative standard deviation was found to 
be 0.237% and 0.069%, respectively. Specificity studies 
were good with results, indicating that the excipients did 
not interfere with the analysis.
The recovery of drug was determined at 80, 100 and 120 
% level. The percent mean recovery was obtained 98.99 for 
Brand I and 99.12 for Brand II. Percent mean recoveries 
greater than 99% with low standard deviation justifies 
the accuracy of the method. The percent mean recovery 
lies within the desirable confidence interval of 98-102%, 
hence it can be said that the proposed method is accurate. 
The calibration curve was repeated three times in a day at 
three different concentrations and the calibration curve 
was repeated three times on three different days at three 
different concentrations. These values confirmed the intra-
day and inter-day precision of the method. The intra-day 
and inter-day % RSD values were calculated which were 
found to be in the range of 0.176-0.177. [Table 2] The 
low %RSD value revealed that the proposed method at 
selected wavelength is precise. The calculated limit of 
detection (LOD) and limit of quantification (LOQ) were 
found to be 0.160 (µg/ml) and 0.534 (µg/ml) respectively. 
The LOD and LOQ showed that the method is sensitive 
for Escitalopram Oxalate. 
Two brands of tablets were analyzed and amount of 
drugs was determined by proposed method; it was in 
good agreement with the label claim. [Table 3] The 
proposed spectrophotometric method for estimation of 
Escitalopram oxalate was found to be simple, precise, 
accurate and sensitive and can be utilized as a quality 
control tool for estimation of Escitalopram Oxalate in 
tablet dosage form.   
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Table 1: Beer’s law data and regression characteristics 
of escitalopram oxalate
Parameters UV spectrophotometric methods
Regression equation Y=0.0488x-0.0006
Slope (b) 48.8x10-3
Intercept (a) 0.6x10-3
Linearity range (µg /ml) 2.003-20.032
Molar absorptivity (Lit/mole/cm) 20.222x103
Correlation Coefficient (r) 0.9999
Table 2:  Summary of validation parameters for 
estimation of escitalopram oxalate by UV-spectroscopy
Parameter Observation
Escitalopram oxalate
Specificity No interference was found w.r.t.# excipients
Linearity (Correlation 
coefficient r)
0.9999
Accuracy* (% Recovery) 98.99% and 99.95%
Precision RSD%
Repeatability (n= 6)
Intra-day (n=3)
Inter-day (days=3)
0.803
0.176
0.177
LOD (µg/ml) 0.160
LOQ (µg/ml) 0.534
*Average of three determinations, #With Respect To
Table 3: Assay of Marketed Formulation
Brand Labeled 
amount 
(mg)
Amount 
found* 
(mg)
% of Labeled 
amount*
%RSD
ESTA 20 20 19.620.084 98.13±0.257 0.429
S CITADEP-10 10 9.93±0.025 99.17±0.421 0.259
*Average of six estimationsZero order spectrophotometric estimation of escitalopram oxalate
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